BOT.AX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 09:10):

Stats
Šios dienos apimtis	3.27M
Vidutinė apimtis	2.57M
Rinkos kapitalizacija	346.53M
EPS	$0 ( 2024-02-25 )
Kita pelno data	( $0 ) 2024-07-28
Last Dividend	$95.85 ( 1996-10-03 )
Next Dividend	$0 ( N/A )
P/E	-22.00
ATR14	$0.00200 (0.93%)

Tūris Koreliacija

Ilgas: 0.12 (neutral)

Trumpas: 0.22 (neutral)

Signal:(40.465) Neutral

Botanix Pharmaceuticals Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Botanix Pharmaceuticals Koreliacija - Valiuta/Žaliavos

0.00
( neutral )

-0.44
( neutral )

Botanix Pharmaceuticals Finansinės ataskaitos

Annual	2023
Pajamos:	$914 973
Bruto pelnas:	$-3.05M (-332.90 %)
EPS:	$-0.00790

FY	2023
Pajamos:	$914 973
Bruto pelnas:	$-3.05M (-332.90 %)
EPS:	$-0.00790

FY	2022
Pajamos:	$2.75M
Bruto pelnas:	$2.61M (94.79 %)
EPS:	$-0.0135

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.00438

Financial Reports:

No articles found.

Botanix Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Botanix Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$81.28	1994-02-18
Last Dividend	$95.85	1996-10-03
Next Dividend	$0	N/A
Payout Date	1996-10-25
Next Payout Date	N/A
# dividends	6	--
Total Paid Out	$510.23	--
Avg. Dividend % Per Year	0.00%	--
Score	1.06	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-11-04)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

1.06

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
TPG.AX	Ex Dividend Knight	2023-09-12	Semi-Annually	0.00%
D2O.AX	Ex Dividend Junior	2023-10-12	Semi-Annually	0.00%
NWH.AX	Ex Dividend Knight	2023-09-21	Semi-Annually	0.00%
ABP.AX	Ex Dividend Junior	2023-06-30	Semi-Annually	0.00%
FPH.AX	Ex Dividend Knight	2023-06-26	Semi-Annually	0.00%
PSQ.AX	Ex Dividend Junior	2023-09-21	Annually	0.00%
AUI.AX	Ex Dividend Knight	2023-08-28	Semi-Annually	0.00%
INA.AX	Ex Dividend Knight	2023-08-25	Semi-Annually	0.00%
SGM.AX	Ex Dividend Junior	2023-10-03	Annually	0.00%
CDP.AX	Ex Dividend Junior	2023-06-29	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-11.08	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.210	1.200	-7.01	-8.41	[0 - 0.3]
returnOnEquityTTM	-0.293	1.500	-4.37	-6.56	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	9.50	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	8.09	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	7.99	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	-858.83	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.00702	2.00	-0.00234	-0.00468	[0 - 30]
freeCashFlowPerShareTTM	-0.0186	2.00	-0.00932	-0.0186	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	-5.76	1.000	-10.00	-10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-11.10	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.0190	0.800	-3.21	-2.57	[0.5 - 2]
Total Score				-3.67

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-31.58	1.000	-3.29	0	[1 - 100]
returnOnEquityTTM	-0.293	2.50	-2.81	-6.56	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0186	2.00	-0.00621	-0.0186	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.00702	2.00	-0.00234	-0.00468	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.106	1.500	-2.62	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-11.17	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.43

Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited engages in the research and development of dermatology and antimicrobial products in Australia. The company engages in development of novel treatments for common skin diseases and infections. Its product pipeline includes Sofpironium Bromide, a drug in development for the treatment of primary axillary hyperhidrosis that has completed Phase 3 clinical programs; BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which has completed Phase IIb clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 that is in Phase IIb clinical trials for the treatment of papulopustular rosacea; and BTX 1204A for the treatment of atopic dermatitis. The company was incorporated in 1984 and is based in Leederville, Australia.